Here are 1-2 brief analogies to describe Tevogen Bio (TVGN):

• Like a clinical-stage Moderna (MRNA) or BioNTech (BNTX), but developing 'off-the-shelf' T-cell treatments for COVID-19 and other complex diseases instead of vaccines.
• It's similar to Novartis (NVS) or Bristol Myers Squibb (BMY), but exclusively focused on making advanced T-cell therapies 'off-the-shelf' and universally accessible for a wide range of conditions, starting with COVID-19.

• TVGN 489: An investigational precision T cell therapeutic designed to address the unmet need of acute-risk COVID-19 patients and a subset of patients suffering from long COVID.

Tevogen Bio (TVGN) is a clinical-stage biotechnology company focused on developing investigational precision T cell therapeutics. As a clinical-stage company, its lead product, TVGN 489, is still in development and has not yet been commercialized.

Therefore, Tevogen Bio does not currently have major customers in the traditional sense of selling products or services to other companies or individuals.

• Lonza Group Ltd. (LONN)
• Waisman Biomanufacturing
• CellGenix GmbH

Ryan Saadi, MD, MPH Chief Executive Officer

Ryan Saadi is the founder and Chief Executive Officer of Tevogen Bio. He also serves as Managing Director and Executive Advisor of the Center for Market Access and Medical Innovation. Dr. Saadi has nearly three decades of experience in healthcare, holding leadership roles within hospital administration, managed care, and life sciences. He is recognized as an innovator in healthcare and an expert in global health policy, market access, clinical development, and research. He is an alumnus of the Harvard Business School Executive Education Program, Yale School of Medicine, and Dhaka Medical College.

Kirti Desai, CPA Chief Financial Officer

Kirti Desai is the Chief Financial Officer of Tevogen Bio. She previously worked at Tevogen Bio Inc.

Neal Flomenberg, MD Chief Scientific Officer and Global R&D Lead

Dr. Neal Flomenberg joined Tevogen Bio as its Chief Scientific Officer in July 2022, following a career spanning over 40 years in academic medicine. Before joining Tevogen, he served as Professor and Chair of the Department of Medical Oncology and Deputy Director of Jefferson's Sidney Kimmel Cancer Center. His work has focused on the care of patients with blood cancers, particularly those undergoing bone marrow or peripheral blood stem cell transplants. He has authored more than 175 peer-reviewed publications.

Sadiq Khan, MBA Chief Commercial Officer and Interim Head of Tevogen Generics

Sadiq Khan leads Tevogen Bio's Global Commercial organization, bringing over 30 years of commercial leadership, operations, and alliance management experience. Prior to Tevogen, he served as Executive Director of Operations & Business Planning at BioCentriq, a contract development and manufacturing organization (CDMO) specializing in cell and gene therapy manufacturing. He also held various leadership positions at Sanofi-Aventis and its predecessor companies, successfully launching and managing multiple products in various markets and therapeutic areas. He holds an MBA cum laude from the University of Illinois at Chicago.

Stephen Chen, MBA Chief Technical Officer

Stephen Chen serves as the Chief Technical Officer for Tevogen Bio, with over 18 years of experience in the biotech industry. His previous roles include Chief Operating Officer and Chief Technical Officer at NKGen Biotech, where he was responsible for technical operations and establishing a clinical GMP manufacturing facility. He has also held positions at ARMO Biosciences, Kite Pharma, and Baxter BioScience.

The key risks to Tevogen Bio (TVGN) primarily stem from its financial position, the inherent uncertainties of clinical-stage biotechnology development, and the evolving market landscape for its lead COVID-19 therapeutic.

1. Precarious Financial Position and Need for Capital: Tevogen Bio operates with a history of significant losses, negative equity, and a rapid cash burn rate, reporting zero revenue in recent quarters. The company's financial health indicators are weak, and it recently executed a 1-for-50 reverse stock split to regain compliance with Nasdaq's minimum bid price requirement, which is often perceived negatively by investors and indicates financial distress. Tevogen will need to raise substantial additional capital to fund its business operations and advance its pipeline, and there is no guarantee that such funding will be available on favorable terms or at all.
2. Clinical Development and Regulatory Approval Risk: As a clinical-stage biotechnology company, Tevogen's success is heavily dependent on the successful execution and completion of preclinical studies and clinical trials for its investigational products, particularly its lead candidate, TVGN 489. Despite positive safety results from initial proof-of-concept trials for TVGN 489, the path to regulatory approval is lengthy, complex, and uncertain, with no guarantee of success. Developing T-cell therapies is also inherently complex, costly, and faces unique manufacturing and logistical challenges. Furthermore, the broader T-cell immunotherapy field is subject to ongoing regulatory scrutiny, including concerns raised by the FDA regarding the risk of T-cell malignancies with certain CAR T-cell immunotherapies.
3. Uncertain Market Demand and Competition for COVID-19 Therapeutics: Tevogen's lead product, TVGN 489, is designed to address acute-risk COVID-19 patients and those with long COVID. However, the market for new COVID-19 therapies is dynamic and uncertain, with changing patient needs, the availability of existing vaccines and treatments, and potentially decreased regulatory urgency. The company's ambitious revenue projections for TVGN 489 may prove unrealistic given the evolving pandemic landscape and intense competition within the pharmaceutical industry.

Tevogen Bio's main product, TVGN 489, targets both acute-risk COVID-19 and Long COVID. The addressable markets for these conditions are significant, both in terms of patient population and economic burden.

Long COVID Market

The addressable market for Long COVID treatments is substantial, driven by a large affected population. In the United States, an estimated 20 million Americans are affected by Long COVID, with other reports indicating approximately 35 million U.S. adults suffered from the condition as of 2023. Tevogen Bio has expanded the potential eligibility for its TVGN 489 therapy to approximately 65% of the U.S. population for Long COVID, by identifying additional HLA targets.

The economic burden associated with Long COVID is considerable, highlighting the potential value of effective treatments. The annual global economic cost of Long COVID is estimated at approximately $1 trillion. In the United States alone, the total economic cost of Long COVID was estimated at $3.7 trillion in a July 2022 update, encompassing lost quality of life, lost earnings, and additional medical expenses. Another estimate places the economic burden in the U.S. between $2.6 trillion and $3.7 trillion.

Acute-Risk COVID-19 Market

For acute COVID-19, particularly in high-risk patients, the global market for COVID-19 infection (which includes treatment, diagnosis, and prevention solutions) was valued at USD 26.82 billion in 2024. This market is projected to grow to USD 70.31 billion by 2032, at a compound annual growth rate (CAGR) of 12.80%.

Specifically for severe acute respiratory syndrome coronavirus infection, encompassing the top 7 markets (U.S., EU4, UK, and Japan), the market reached a value of USD 23.8 billion in 2024. This market is expected to grow to USD 77.0 billion by 2035, exhibiting a CAGR of 11.29% during the period of 2025-2035. TVGN 489 is also designed to address acute COVID-19 infection in high-risk immunocompromised patients.

Tevogen Bio (TVGN) anticipates several key drivers for future revenue growth over the next 2-3 years, primarily stemming from the advancement and commercialization of its precision T cell therapeutics pipeline and strategic business initiatives.

1. Commercialization and Market Expansion of TVGN 489: Tevogen Bio projects significant revenue from its lead investigational precision T cell product, TVGN 489, designed for acute-risk COVID-19 patients and those with Long COVID. The company forecasts nearly $1 billion in top-line revenue in its launch year for its specialty care pipeline, which includes TVGN 489, with a cumulative 5-year estimate ranging between $18 billion and $22 billion. Furthermore, Tevogen plans to expand TVGN 489's target population to include patients aged 65 and older, thereby broadening its market potential. The company is also actively preparing for clinical manufacturing of TVGN 489 and intends to collaborate with government initiatives, patient organizations, and healthcare providers to accelerate development and maximize patient access once regulatory pathways permit.

2. Advancement and Launch of Oncology Pipeline Products: Tevogen Bio has provided a revenue forecast for its oncology pipeline, anticipating $1 billion in its first year of product launch and a cumulative 5-year estimate of $10 billion to $14 billion. This pipeline includes several product candidates targeting various cancers, such as TVGN 920 for cervical cancer prevention, TVGN 930 for EBV-associated lymphomas, and TVGN 960 for mouth and throat cancer.

3. Launch of TVGN 116 for Liver Cancer Prevention: A specific pipeline product, TVGN 116, focused on liver cancer prevention in high-risk chronic Hepatitis B infections, is expected to be a substantial revenue contributor. Tevogen estimates a cumulative 5-year top-line revenue of approximately $6.5 billion for TVGN 116. The progress with TVGN 489 highlights the rapid pace at which such milestones can be achieved for pipeline products.

4. Strategic Acquisitions: Tevogen Bio is actively exploring potential strategic acquisitions to bolster its immunotherapy and artificial intelligence platforms. Initial assessments suggest that these potential acquisitions could generate over $50 million in annual revenues, contributing positively to the company's financial outlook. These initiatives align with Tevogen's commitment to innovation, affordability, and disciplined growth.

Share Repurchases

• In July 2024, Tevogen Bio announced it was considering options, including a potential share repurchase, to enhance stockholder value.
• As of March 2026, Tevogen Bio does not anticipate utilizing more than 1% of its authorized shares for purposes including "at-the-market" offerings over the next 12 months or until the company becomes cash-flow positive, implying no significant share repurchases are currently planned.

Share Issuance

• In June 2023, Tevogen Bio announced plans to go public through a business combination with Semper Paratus Acquisition Corporation, a SPAC, which involved the issuance of shares to Tevogen Bio stockholders and the SPAC's sponsor.
• In June 2024 and August 2024, the company filed and had declared effective a registration statement on Form S-1 to register the issuance of shares underlying warrants (issued in 2021) and earnout shares from the SPAC merger agreement, clarifying that it did not relate to new dilutive issuances.
• In July 2025, Tevogen Bio entered into an "at-the-market" equity offering agreement to potentially issue and sell up to $50 million of its common stock.

Inbound Investments

• In January 2025, Tevogen Bio received $2 million in non-dilutive grant funding from KRHP LLC, an entity affiliated with an existing investor, with an expectation of receiving up to an additional $8 million for a total of $10 million to advance its AI-powered drug discovery platform.
• In August 2024, Tevogen Bio secured a $6.0 million Series C Preferred Stock investment from The Patel Family, LLP, with closings of $4.0 million and $2.0 million in August and September 2024, respectively.
• In February 2024, the company obtained $2.0 million from a securities purchase agreement for Series A Preferred Stock.

Outbound Investments

• In March 2026, Tevogen Bio entered into a non-binding Letter of Intent to evaluate a potential acquisition of Apozeal Pharmaceutical Inc. to strengthen its generics platform, and is actively considering other acquisitions in life sciences.
• In February 2026, Tevogen Bio agreed to evaluate a potential transaction with Sciometrix Inc., a privately held healthcare technology and value-based care solutions provider.

Capital Expenditures

• In April 2025, Tevogen Bio entered an agreement for the development or acquisition of a turn-key facility to support in-house preclinical research and GMP cell therapy production, and is actively establishing its own GMP manufacturing facility.
• Capital expenditures are primarily focused on building infrastructure, advancing AI capabilities (Tevogen.AI), and strengthening internal operational capacity.
• Tevogen Bio's CEO, Ryan Saadi, personally contributed $500,000 for the build-out and first-year operating costs of the company's new headquarters in Warren, New Jersey.